Tesamorelin
6 research papers indexed
Stanley 2019 — Tesamorelin for NAFLD in HIV
99
The Lancet HIV
·2019RCTHumanNon-alcoholic fatty liver disease in people with HIVSourceRCT
FDA Egrifta WR Prescribing Information 2025
0
FDA NDA 22-505
·2025RegulatoryHIV lipodystrophySourceFDA
Stanley 2019 — Tesamorelin NAFLD Study
0
Lancet HIV
·2019RCTHumanNAFLD in HIVSourceRCT
Clemmons 2017 — Tesamorelin T2D Safety Study
0
PLOS ONE
·2017RCTHumanGlycemic safety in type 2 diabetesSourceRCT
Falutz 2010 — JCEM Pooled Phase 3 Analysis
0
Journal of Clinical Endocrinology and Metabolism
·2010Pooled AnalysisHumanHIV-associated lipohypertrophySourcePooled Analysis
Falutz 2007 — NEJM Pivotal Phase 3 Tesamorelin
0
New England Journal of Medicine
·2007RCTHumanHIV-associated lipodystrophySourceRCT